25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 25 of 25 clinical reviews.
A clinician-level review of how thymosin alpha-1 (thymalfasin) may affect cognitive function, covering neuroimmune mechanisms, key trials, dosing considerations, and what patients and prescribers need to know.
A source-grounded review of thymosin alpha-1 and muscle preservation, including the absence of lean-mass trials, GLP-1 body-composition data, sepsis evidence, and FDA compounding concerns.
A clinician-level review of how thymosin alpha-1 (thymalfasin) affects appetite and cravings, covering mechanisms, clinical trial data, dosing protocols, and what patients can expect during treatment.
A clinician-level review of thymosin alpha-1 (thymalfasin) in autoimmune disease: immunomodulatory mechanisms, trial evidence, risk-benefit analysis, dosing protocols, and monitoring parameters for prescribers.
A clinician-level review of thymosin alpha-1 (thymalfasin) and its effects on bone density, osteoclast regulation, and skeletal immune crosstalk, with primary-literature citations and dosing context.
A physician-level review of thymosin alpha-1 (thymalfasin) and cancer risk signals, covering immunostimulatory mechanisms, clinical trial data, oncology adjunct use, and current 503A compounding context.
A physician-reviewed analysis of thymosin alpha-1 (thymalfasin) cardiovascular effects, covering inflammation pathways, clinical trial data, immune-cardiac crosstalk, and long-term safety signals for clinicians and informed patients.
A physician-reviewed comparison of compounded thymosin alpha-1 and branded thymalfasin (Zadaxin), covering pharmacology, clinical trial data, dosing, purity standards, regulatory status, and how to choose between them.
A MD/PharmD-level review of thymosin alpha-1 (thymalfasin) clinical evidence organized by GRADE certainty ratings, covering hepatitis B, hepatitis C, cancer, sepsis, and immune-deficiency applications with primary-literature citations.
A clinician-level review of thymosin alpha-1 (thymalfasin) effects on hair and skin, covering immune mechanisms, clinical trial data, reported changes, and practical guidance for patients and providers.
A physician-reviewed deep dive into how thymosin alpha-1 (thymalfasin) affects liver function, covering hepatitis B and C trials, ALT/AST normalization data, fibrosis markers, and current 503A compounding status.
A clinical deep-dive into how thymosin alpha-1 (thymalfasin) affects mood, neuroinflammation, fatigue, and mental health outcomes, with primary-literature citations and physician-reviewed guidance.
A physician-reviewed guide to thymosin alpha-1 (thymalfasin) and its effects on metabolism, mitochondrial function, and energy expenditure, with primary-literature citations throughout.
A physician-reviewed clinical breakdown of thymosin alpha-1 (thymalfasin) microdosing protocols, standard dosing data from hepatitis and cancer trials, immune-modulation mechanisms, and what 503A compounding regulations mean for prescribers and patients.
MD/PharmD-level guide to diagnosing and resolving thymosin alpha-1 (thymalfasin) plateaus, including dose optimization, biomarker monitoring, adjunct strategies, and non-responder identification based on primary literature.
A physician-level review of thymosin alpha-1 (thymalfasin) use after bariatric surgery, covering immune dysregulation, dosing, absorption considerations, safety, and current evidence from primary literature.
A clinician-level guide to the thymosin alpha-1 (thymalfasin) pre-surgery hold window, covering pharmacology, immune-modulation risk, recommended discontinuation timing, and post-operative restart protocols based on current primary literature.
Do patients experience immune rebound after stopping thymosin alpha-1 (thymalfasin)? A physician-reviewed deep-dive into the clinical evidence, proposed mechanisms, and practical discontinuation guidance.
A physician-reviewed analysis of thymosin alpha-1 (thymalfasin) and the kidneys: renoprotective mechanisms, clinical trial data, nephrotoxicity risk, and dosing considerations for patients with chronic kidney disease.
A clinical-depth guide to thymosin alpha-1 (thymalfasin) seasonal dosing strategies, immune timing, and evidence-based protocols for practitioners and informed patients.
A physician-reviewed guide to how thymosin alpha-1 (thymalfasin) affects sexual function, covering mechanisms, clinical trial data, immune-sex hormone connections, and practical protocols.
A deep-dive into how thymosin alpha-1 (thymalfasin) affects sleep architecture, immune-sleep crosstalk, cytokine regulation, and clinical outcomes. Reviewed by the HealthRX medical team.
MD/PharmD-level guide to dosing, timing adjustments, storage, and immunologic rationale for thymosin alpha-1 (thymalfasin) during international travel and timezone shifts. Includes primary literature, clinical frameworks, and FAQ.
A physician-level guide to restarting Thymosin Alpha-1 (thymalfasin) after acute illness, covering timing, dosing protocols, safety checkpoints, and the clinical evidence base from hepatitis, oncology, and sepsis trials.
A week-by-week clinical guide to thymosin alpha-1 (thymalfasin) for the first month of therapy: mechanism, expected immune changes, dosing protocols, and what the primary literature says about each phase.